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Abstract
Observational studies have indicated that soya food consumption is inversely associated with blood pressure (BP). Evidence from random-
ised controlled trials (RCT) on the BP-lowering effects of soya protein intake is inconclusive. We aimed to evaluate the effectiveness of soya
protein intake in lowering BP. The PubMed database was searched for published RCT in the English language through to April 2010, which
compared a soya protein diet with a control diet. We conducted a random-effects meta-analysis to examine the effects of soya protein on
BP. Subgroup and meta-regression analyses were performed to explore possible explanations for heterogeneity among trials. Meta-analyses
of twenty-seven RCT showed a mean decrease of 2·21 mmHg (95 % CI 24·10, 20·33; P¼0·021) for systolic BP (SBP) and 1·44 mmHg (95 %
CI 22·56, 20·31; P¼0·012) for diastolic BP (DBP), comparing the participants in the soya protein group with those in the control group.
Soya protein consumption significantly reduced SBP and DBP in both hypertensive and normotensive subjects, and the reductions were
markedly greater in hypertensive subjects. Significant and greater BP reductions were also observed in trials using carbohydrate, but not
milk products, as the control diet. Meta-regression analyses further revealed a significantly inverse association between pre-treatment BP
and the level of BP reductions. In conclusion, soya protein intake, compared with a control diet, significantly reduces both SBP and DBP,
but the BP reductions are related to pre-treatment BP levels of subjects and the type of control diet used as comparison.
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High blood pressure (BP), or hypertension, with a high preva-
lence in developed countries, is increasing dramatically in
developing countries, in parallel with economic development.
It has become a serious burden of global public health, influ-
encing approximately 42 % of the population in England and
one billion individuals worldwide(1,2). Furthermore, hyperten-
sion has been identified as a large but modifiable risk factor
for cardiovascular mortality, which is the leading cause of
death in Europe and North America. Considerable attention
therefore should be paid to the prevention and control of
hypertension.
Soya has received an increasing scientific interest for its
beneficial effects on cardiovascular health since the US Food
and Drug Administration (Silver Spring, MD, USA) approved
a health claim in 1999 that a daily intake of 25 g of soya pro-
tein may reduce heart disease. Isoflavones in soya protein, a
class of phyto-oestrogens acting as oestrogen mimics, are
suggested to have potential hypotensive effects(3–5). However,
a recent meta-analysis by Hooper et al.(6) has shown that iso-
flavone extracts did not affect BP, though the result for systolic
BP was close to significance. Also, three trials(7–9) published
subsequently to that meta-analysis did not yield significant
results either. Moreover, two trials(7,8) showed that isoflavone
extract intervention resulted in an increase in BP compared
with control. On the basis of the current evidence, we believe
with some confidence that isoflavone extracts have no
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significant effects on BP. On the other hand, numerous epide-
miological studies have been carried out to evaluate the effects
of soya protein or soya foods on cardiovascular health as well
as BP reductions. Observational studies(10–12) have indicated
that soya protein intake or soya food consumption might be
inversely associated with BP. Several randomised controlled
trials (RCT) have documented a BP-lowering role of
soya(3,5,13,14), whereas others have suggested no effect. A pre-
vious meta-analysis(6) reported that soya protein isolate, but
not other soya products or components, significantly reduced
diastolic BP (DBP). However, that study was not primarily
designed to assess the effects of soya protein or isoflavones
on BP, and sources of heterogeneity were not explained.
With newly emerging evidence supporting a BP-lowering
role of soya protein rather than isolated isoflavones, we
aimed to conduct an updated and comprehensive meta-
analysis of RCT to evaluate the effects of soya protein on
BP reductions, and to explore the potential sources of




We searched the PubMed database (National Library of Medi-
cine, Bethesda, MD, USA) through to April 2010 for published
studies in the English language using search terms ‘soya OR
soya protein OR soybeans OR phytoestrogens OR isoflavones’
and ‘hypertension OR blood pressure’. In addition, we carried
out a manual search using reference lists of original articles
and recent reviews. Each published paper was independently
reviewed and relevant information was extracted by three
authors ( J.-Y. D., X. T. and Z.-W. W.).
Study selection
To be included in our analysis, a study was restricted to RCT
conducted in human subjects and reported a net change in
systolic BP (SBP) and DBP during the intervention with their
corresponding standard deviations, or appropriate data to cal-
culate these values. In one study, two independent strata
(normotension v. hypertension) were included; thus, it was
treated as two trials.
Major reasons for exclusion were as follows: (1) using iso-
flavone extracts as treatment; (2) non-randomised treatment
allocation; (3) lack of BP data; (4) a systematic difference
between the intervention and control groups other than
soya protein; (5) absence of a concurrent control group; (6)
recurrent publication of data already represented in the pre-
sent analysis.
Data extraction
We recorded the study characteristics as follows: (1) first
author’s name, publication year and country of origin; (2)
number of participants; (3) mean age, age range, sex
distributions and health status of participants; (4) design
details, including whether parallel or cross-over and open,
single blind or double blind; (5) study duration; (6) dosage
of soya protein and isoflavones, placebo and other treatment
interventions; (7) type of soya protein; (8) mean BP at base-
line. The Jadad score, a scale that ranges from 0 to 5 accord-
ing to the descriptions of randomisation, blinding and
reporting of participant withdrawals, was used to measure
the quality of each trial(15).
Statistical analysis
Net changes in SBP and DBP at the end of the intervention
were calculated, if not reported. For studies reporting only
the mean difference between the treatment and control
groups, we set the control group’s mean change as zero and
the treatment group’s mean change as the reported mean
difference. Standard errors, CI and P values were converted
to standard deviations for the analyses. When the standard
deviation for paired differences was not reported, we calcu-
lated it from the standard deviation at baseline and at the
end of the follow-up on the basis of the method of Follmann
et al.(16), assuming a correlation coefficient of 0·5 between
initial and final BP. We assumed equal variances during the
trial and between the treatment and control groups.
With each trial weighted by the reciprocal of the variance
for BP change, we calculated a weighted mean difference
and its corresponding 95 % CI. Both fixed- and random-effects
models were used. The homogeneity of effect size across trials
was tested by Q statistics (P,0·10 was considered hetero-
geneous). If there was significant heterogeneity among the
studies, the random-effects model was used; otherwise, the
fixed-effects model was acceptable. We also examined the I 2
statistic, which measures the percentage of the total variation
across studies that is due to heterogeneity, rather than
chance(17). A sensitivity analysis was conducted to examine
the influence of various exclusion criteria on the overall
effect sizes.
To explore the influence of covariates on the net change in
BP, we carried out a series of subgroup analyses. Subgroups
were selected based on biological plausibility, study design
and participant characteristics. Furthermore, we conducted a
meta-regression analysis to estimate the effects of various
study characteristics on the effect size. Covariates for meta-
regression analysis were selected based on the results of the
subgroup analysis and biological knowledge. For each trial,
the covariates were calculated as average values of the treat-
ment and control groups at baseline. Mean aortic pressure
was used as pre-treatment BP. When information on mean
values was absent, for example dosage of soya protein, we
estimated it as the median of the remaining trials.
To assess the publication bias, we performed both Egger’s
and Begg’s tests(18,19), and inspected the funnel plots as
well. All analyses were performed using STATA version 10.0
(StataCorp, College Station, TX, USA). A P value ,0·05 was
considered to be statistically significant, unless otherwise
specified.
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Table 1. Characteristics of all trials included in the present meta-analysis















Kurowska (1997)(20) Open, X 32 55 Soyabean products Milk 31 NR 4 131·0/77·0 2
Washburn (1999)(21) DB, X 51 51 SPI Carbohydrate 20 34 6 132·0/82·0 5
Burke (2001)(22) Open, P 18 55 SPI Maltodextrin 66 23 8 134·8/76·9 2
Hermansen (2001)(23) DB, X 20 63·6 SPI Casein 50 160 6 130·0/78·0 4
Teede (2001)(13) DB, P 179 NR SPI Casein 40 116 12 129·0/76·0 5
Jayagopal (2002)(24) DB, X 32 62·5 SPI Cellulose 30 132 12 147·1/82·1 5
Jenkins (2002)(25) Open, X 41 62·2 Soya foods Low-fat dairy 50 73 4 124·0/78·0 2
Rivas (2002)(3) DB, P 40 50 Soya milk Cow skimmed milk 18 143 12 153·4/99·8 4
Allison (2003)(26) Open, P 74 50 Soya-based meal Placebo NR NR 12 117·7/76·9 2
Cuevas (2003)(27) DB, X 18 59 SPI Caseinate 40 80 4 132·0/73·0 4
Meyer (2004)(28) Open, X 23 54 Soya foods Dairy 30 80 5 132·0/77·0 1
Puska (2004)(29) DB, P 143 58 SPI Milk 41·4 153 8 131·2/80·8 5
Sagara (2004)(30) DB, P 50 52·2 SPI Placebo 20 80 5 138·0/84·0 4
Anderson (2005)(31) Open, P 52 50 Soya-based meal Milk-based meal NR NR 12 125·6/69·3 2
He 1 (2005)(14) DB, P 174 51 SPI Carbohydrate 40 76·4 12 135·0/85·0 5
He 2 (2005)(14) DB, P 102 51 SPI Carbohydrate 40 76·4 12 144·0/92·0 5
Hermansen (2005)(32) DB, P 89 59 SPI Casein 30 100 24 133·0/80·8 5
Kreijkamp (2005)(33) DB, P 175 66·7 SPI Milk 25·6 99 52 140·8/75·2 5
Lukaczer (2006)(34) Open, P 42 54·6 SPI Standard diet 30 34 12 126·5/83·5 3
Teede (2006)(4) DB, X 38 60 SPI Gluten 40 118 12 142·9/84·2 5
Anderson (2007)(35) SB, P 43 45 Soya-based shakes Casein 40 150 21 124·1/81·0 2
Azadbakht (2007)(36) Open, X 42 NR Texture soya protein DASH diet 15 84 8 136·0/87·0 3
Matthan (2007)(37) Open, X 28 65 Soyabean Animal protein 37·5 132 6 120·0/73·5 2
Welty 1 (2007)(5) Open, X 12 58·3 Soya nuts Non-soya protein 25 101 8 116·0/69·0 1
Welty 2 (2007)(5) Open, X 48 53·5 Soya nuts Non-soya protein 25 101 8 152·0/88·0 1
Santo (2008)(38) DB, P 19 24 SPI Milk 25 97 4 110·8/69·5 5
Wong (2010)(39) Open, X 23 58·1 Soya foods Low-fat dairy 30 61 4 122·8/76·7 3
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Results
Characteristics of the studies
After our complete review, twenty-five studies(3–5,13,14,20–39)
including twenty-seven trials met the inclusion criteria.
Characteristics of the trials included in the present meta-
analysis are presented in Table 1. The trials published
between 1997 and 2010 varied from 12 to 276 participants,
with a median of 42 and a total number of 1608. Of the
twenty-seven trials, nine were conducted in the USA, eight
in Europe and ten in other countries. All trials were conducted
in adults, with ages ranging from 18 to 75 years. The subjects’
initial mean BP ranged from 110 to 153 mmHg for SBP, and
from 69 to 100 mmHg for DBP. Of the twenty-six trials that
reported the sex distribution, eight consisted entirely of
women, of which six were conducted among post-menopau-
sal women, and two trials consisted entirely of men. There
were five trials(3–5,14,22) conducted only in hypertensive sub-
jects (210 participants) with a mean baseline BP of 145·2/
90·5 mmHg, among which two trials reported antihypertensive
therapy use and the other three did not. There were eleven
trials that included only normotensive subjects (714 partici-
pants) with a mean baseline BP of 126·8/77·9 mmHg. The
remaining eleven trials included both hypertensive and
normotensive subjects. There were two studies(23,24) con-
ducted in patients with type 2 diabetes. Of the twenty-seven
trials, fourteen were parallel-designed, and the rest had a
cross-over design. The duration of the intervention lasted
from 4 to 52 weeks, with a median of 8 weeks. Treatment
was double blind in fourteen trials, single blind in one trial
and open in twelve trials. There were fifteen trials that used
soya protein isolate containing isoflavones and twelve that
used other soya foods. Most of the control groups received
casein or milk. Dosage of soya protein varied from 18 to
66 g/d, with a median of 30 g/d. Dosage of isoflavones con-
tained in soya protein varied from 23 to 160 mg/d, with a
median of 100 mg/d.
Net changes in blood pressure
Tests for heterogeneity indicated that the treatment effect was
significantly different across studies (P,0·001 for SBP and
P,0·001 for DBP). I 2 values were 65·7 % for SBP and 61·5 %
for DBP. Compared with control, intervention was associated
with an average net change in BP ranging from 217·0 to
5·0 mmHg for SBP and 212·2 to 4·0 mmHg for DBP. For
SBP, a trend towards intervention-related reduction in BP
was observed in seventeen trials, with five trials showing a sig-
nificant reduction. For DBP, a trend towards intervention-
related reduction in BP was observed in nineteen trials, with
a significant reduction in five trials. Overall pooled estimates
of the effect of soya protein were 22·21 mmHg (95 % CI
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Fig. 1. Pooled effect size of soya protein with isoflavones on systolic blood pressure. WMD, weighted mean difference.
























bridge.org/core . IP address: 136.56.14.111 , on 05 Feb 2021 at 16:09:18 , subject to the Cam
bridge Core term






24·10, 20·33; P¼0·021) for SBP (Fig. 1) and 21·44 mmHg
(95 % CI 22·56, 20·31; P¼0·012) for DBP (Fig. 2).
Sensitivity analysis
Table 2 presents the results of sensitivity analysis that
excluded trials based on different criteria. Overall pooled esti-
mates for treatment effects in BP changed little in the sensi-
tivity analysis.
Stratified analysis
Table 3 shows the results from stratified analyses. SBP and
DBP were significantly reduced in both the hypertensive
and normotensive groups. Furthermore, the mean decrease
in the hypertensive group was 8·58 mmHg (95 % CI 215·10,
22·06; P¼0·010) for SBP and 5·24 mmHg (95 % CI 29·40,
21·08; P¼0·014) for DBP, markedly greater than that in the
normotensive group. Significant BP reductions in response
to the intake of soya protein were also observed in trials
using carbohydrate as the control diet, with a longer duration,
using soya protein isolate as treatment, and in trials employing
a parallel design. Moreover, the reductions tended to be
greater among trials using carbohydrate than those using
milk or casein as the control diet, among trials with a parallel
design than those with a cross-over design and among trials
with the intervention duration of at least 12 weeks than
those with less than 12 weeks.
Meta-regression analysis
We first conducted univariate meta-regression analyses for
each of the following variables: pre-treatment BP; duration
of intervention; sample size; BMI; dosage of soya protein;
dosage of soya isoflavones. There was a significant inverse
association of effect size with pre-treatment BP for both SBP
(Fig. 3) and DBP (Fig. 4), but not with other covariates (all
P.0·3; e.g. P values are 0·791 and 0·492 for isoflavone
dosage v. net changes in SBP and DBP, respectively). In our
multivariate meta-regression, pre-treatment BP remained sig-
nificant after adjustment for the other covariates (P¼0·011
for SBP and P¼0·039 for DBP). Pre-treatment BP was there-
fore proved to be a significant and independent predictor
for heterogeneity, strengthening the results of the present sub-
group meta-analyses.
Publication bias
There was no sign of publication bias when examining the
funnel plots (plot not shown). Results from Begg’s and
Egger’s tests also did not indicate the evidence of publication
bias (SBP: Begg P¼0·297, Egger P¼0·988; DBP: Begg
P¼0·381, Egger P¼0·243).
Study WMD (95 % CI)
Overall (I2 = 61·5 %, P = 0·000)





















































































Fig. 2. Pooled effect size of soya protein with isoflavones on diastolic blood pressure. WMD, weighted mean difference.
























bridge.org/core . IP address: 136.56.14.111 , on 05 Feb 2021 at 16:09:18 , subject to the Cam
bridge Core term






Table 2. Pooled estimates of treatment effects on blood pressure through sensitivity analyses
(Number of trials, I 2 and 95% confidence intervals)













heterogeneity I 2 (%)
All trials 27 22·21 24·10, 20·33 0·021 ,0·001 65·70 27 21·44 22·56, 20·31 0·012 ,0·001 61·50
All trials except outliers 26 21·59 23·17, 20·00 0·05 0·003 48·90 26 21·08 22·04, 20·11 0·029 0·005 46·40
Blinded trials 15 22·90 25·49, 20·31 0·028 ,0·001 71·40 15 21·93 23·53, 20·34 0·017 ,0·001 67·80
Trials using soya protein isolate 16 21·99 23·91, 20·07 0·042 0·036 43·80 16 21·57 22·76, 20·38 0·01 0·044 42·00
Trials with Jadad score $3 16 22·82 25·29, 20·36 0·025 ,0·001 69·40 16 22·02 23·49, 20·56 0·007 ,0·001 64·30
Trials excluding diabetics 25 22·28 24·27, 20·29 0·025 ,0·001 67·70 25 21·55 22·75, 20·35 0·012 ,0·001 64·20
Table 3. Pooled estimates of treatment effects on blood pressure in subgroups of trials
(Number of trials, I 2 and 95% confidence intervals)
Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg)
Groups Trials (n)
Net
change 95% CI P for trend
P for
heterogeneity I 2 (%) Trials (n)
Net
change 95% CI P for trend
P for
heterogeneity I 2 (%)
Hypertension
Yes 5 28·58 215·09, 22·06 0·01 ,0·001 84·1 5 25·24 29·40, 21·08 0·014 ,0·001 81·6
No 11 22·27 23·77, 20·76 ,0·001 0·175 24 11 21·21 22·19, 20·23 0·016 0·339 11·1
Study design
Parallel 14 23·08 25·95, 20·21 0·035 ,0·001 73·6 14 22·25 23·95, 20·55 0·009 ,0·001 65·1
Cross-over 13 21·07 23·24, 1·10 0·332 0·073 39·1 13 20·41 21·62, 0·79 0·5 0·136 30·9
Sample size
# 42 15 22·28 25·37, 0·81 0·149 ,0·001 69 15 21·30 23·04, 0·44 0·143 ,0·001 0·638
. 42 12 22·28 24·60, 0·03 0·053 0·003 61·2 12 21·74 23·07, 20·42 0·01 0·034 0·475
Type of soya protein
Soya protein isolate 15 21·99 23·91, 20·07 0·042 0·036 43·8 15 21·57 22·76, 20·38 0·01 0·044 42
Soya foods 12 22·78 26·53, 0·96 0·145 ,0·001 78·3 12 21·41 23·52, 0·69 0·188 ,0·001 71
Type of control diet
Milk or casein 16 22·00 25·00, 0·96 0·184 ,0·001 72 16 21·33 23·04, 0·37 0·126 0·001 59·1
Carbohydrate 6 24·52 26·42, 22·63 0·002 0·166 36·1 6 23·01 25·05, 20·97 0·004 0·079 49·3
Duration (weeks)
# 8 15 21·15 23·27, 0·97 0·287 0·094 34·3 15 20·78 22·08, 0·52 0·237 0·09 34·8
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Discussion
The present study identified significant reductions in the over-
all estimates in both SBP and DBP during soya protein inter-
ventions. Soya protein consumption significantly reduced
SBP and DBP in both hypertensive and normotensive subjects,
and the reductions were markedly greater in hypertensive
subjects than those in normotensive subjects. Meta-regression
analyses further revealed a significantly inverse association
between pre-treatment BP and the level of BP reductions. In
addition to pre-treatment BP, the type of control diet used as
a comparison also has an impact on the BP reductions.
Our findings have potential public health implications.
Although the BP reductions reported here are moderate at
the individual level, a reduction of 4–5 mmHg in SBP and
2–3 mmHg in DBP would be expected to substantially
reduce the risk of stroke (by about 20 %), CHD (by 10 %)
and all-cause mortality (by 8 %) at the population level(40).
Given the high prevalence of hypertension(1,2), even a slight
reduction in BP may contribute to a considerable public
health benefit from soya protein consumption. Moreover,
when used for other purposes, such as improving lipid pro-
files(41,42), the moderate hypotensive effects of soya protein
doubtlessly provide extra benefits.
The observed substantial heterogeneity is most probably
explained by pre-treatment BP and the type of control diet.
It is probable that subjects with higher BP have more room
for improvement. In fact, the study by Rivas et al.(3) that
enrolled mild-to-moderate hypertensive patients and reported
substantial BP reductions has been partly responsible for the
observed heterogeneity, as exclusion of this outlier resulted
in I 2 values ,50 % for both SBP and DBP. Furthermore,
trials(5,13,14,20,26,31,34,35,37–39) conducted in normotensive sub-
jects yielded consistent and significant, although small, BP
reductions, with little evidence of heterogeneity (P¼0·175
for SBP and P¼0·339 for DBP). This is probably because
normotensive subjects are evidently healthy and are unlikely
to take antihypertensive drugs that may potentially mask the
effects of soya protein on BP.
Of note, the type of control diet appeared to play an import-
ant role in the effects of soya protein on BP. Growing evidence
shows that milk product consumption has potential benefits
on BP regulations(43). When compared with milk or casein,
soya protein showed small but not significant reductions in
BP, which indicated soya protein may not be superior to
milk products in improving BP. When compared with carbo-
hydrate, soya protein consumption produced greater and sig-
nificant BP reductions. These findings are consistent with the
current evidence that partial substitution of refined carbo-
hydrate with dietary protein can lower BP(44,45). Thus, further
studies of soya protein on BP should take the type of control
diet into consideration.
In addition to pre-treatment BP and type of control diet,
other characteristics of trials are worth considering, including
duration of intervention and study design. Although the
association of intervention duration with BP reductions was
not found in the meta-regression analyses, results from sub-
group analyses indicated that duration of at least 12 weeks
would be necessary for intervention. Parallel-designed trials
showed a greater reduction in BP than cross-over-designed
trials. This is possibly because parallel-designed trials usually
have longer duration that was associated with significant BP
reductions as observed earlier. It is also possible that carry-
over effects have residual impacts on BP reductions, as wash-
out periods were short in most cross-over trials.
The present study has several strengths. First, it provides a
comprehensive report of the effects of soya protein consump-
tion on BP, based on the pooled evidence from twenty-seven
RCT conducted in a wide range of geographical locations. The
participant characteristics such as patient background, base-
line BP status and ethnicity varied across trials, indicating
that our findings might have a certain degree of external val-
idity to be generalised to a broader population. Second, com-
pared with the previous meta-analysis(6), the present analysis
identified and included thirteen more RCT through an updated
search. The enlarged sample size enhanced the power to
detect a significant difference and provide more precise esti-
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Fig. 3. Net change in systolic blood pressure according to pre-treatment
blood pressure (r 20·54, P¼0·006). Diameters of circles depend on the



































Pre-treatment blood pressure (mmHg)
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Fig. 4. Net change in diastolic blood pressure according to pre-treatment
blood pressure (r 20·45, P¼0·024). Diameters of circles depend on the
weights in the random-effects model.
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analysis to explore sources of heterogeneity. We also excluded
studies in which other dietary factors were substantially differ-
ent other than soya protein; therefore, soya protein with iso-
flavones was more likely to be the major contributor to the
BP-lowering effects. Third, we investigated the potential
sources of substantial heterogeneity across studies by a
series of subgroup and meta-regression analyses, thereby
increasing the clinical relevance of our conclusions and the
scientific understanding of the relevant studies(46). In addition,
sensitivity analyses supported the robustness of our findings,
and there was little evidence of publication bias in the present
study.
Limitations in the present study should also be acknowl-
edged. Substantial heterogeneity across trials that makes our
findings complicated to interpret is the primary one. However,
we have identified the major sources of inconsistency through
a series of subgroup and meta-regression analyses. Since some
trials were not primarily designed to test the hypotensive
effects of soya protein, a rigorous methodology for measuring
BP and the use of antihypertensive medications among partici-
pants were seldom reported. Likewise, unmeasured dietary
factors that potentially influenced BP outcomes, such as diet-
ary Na and K intake during the intervention, may not be con-
trolled and balanced. In addition, there were only five
trials(3–5,14,22) conducted in hypertensive participants, and
the pooled results in this target group showed an even
higher degree of heterogeneity. For all of these reasons, the
findings of the present meta-analysis should be considered
with caution, and further high-quality large-scale RCT are war-
ranted, especially in the hypertensive population.
The underlying mechanisms by which soya protein with
isoflavones may influence BP remain unclear. Isoflavones in
soya are widely considered as the major contributors to the
hypotensive effects of soya(3–5). It is plausible that isoflavones,
as oestrogen mimics, may exhibit antihypertensive activities
by stimulating the production of the potent vasodilator
NO(47). Isolated isoflavones, however, appear to have little
effect on BP as observed previously, suggesting the necessity
for isoflavones to be ingested in combination with soya pro-
tein. Alternatively, hypotensive effects of soya may be
mediated not only by oestrogenic mechanisms, but also by
other soya components. Arginine, for example, which is a pre-
cursor of NO and with a high content in soya protein, might
also exert BP-lowering effects(48). Additionally, pinitol isolated
from soyabeans has been documented to significantly
decrease BP in patients with type 2 diabetes(49).
Equol, a metabolite of the soya isoflavone daidzein pro-
duced by gut bacteria, has recently received considerable
interest due to its higher bioactivity compared with other iso-
flavones(50). Because only approximately 30–50 % of the
population is able to metabolise daidzein to equol, conflicting
results from previous studies have led to the ‘equol hypoth-
esis’ that equol producers are more likely to benefit from con-
suming soya foods than non-equol producers(50). However,
several clinical studies(28,33,51) investigating the effects of
soya isoflavones on BP have observed no significant differ-
ence between equol producers and non-equol producers.
Limitations of these studies including small sample sizes may
result in insufficient statistical power to detect the difference.
Thus, the equol hypothesis is not supported by the current
evidence and deserves further study.
Conclusions
In summary, current evidence demonstrates that soya protein
intake, compared with a control diet, significantly reduces
both SBP and DBP, but the BP reductions are related to pre-
treatment BP levels of subjects and the type of control diet
used as a comparison.
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